Rocket Pharmaceuticals (RCKT) Common Equity (2016 - 2025)
Historic Common Equity for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $313.7 million.
- Rocket Pharmaceuticals' Common Equity fell 488.28% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 488.28%. This contributed to the annual value of $463.2 million for FY2024, which is 595.65% down from last year.
- Rocket Pharmaceuticals' Common Equity amounted to $313.7 million in Q3 2025, which was down 488.28% from $354.2 million recorded in Q2 2025.
- Rocket Pharmaceuticals' 5-year Common Equity high stood at $541.1 million for Q3 2023, and its period low was $313.7 million during Q3 2025.
- Its 5-year average for Common Equity is $429.8 million, with a median of $441.5 million in 2024.
- Per our database at Business Quant, Rocket Pharmaceuticals' Common Equity skyrocketed by 10081.71% in 2021 and then plummeted by 3905.39% in 2024.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Common Equity stood at $454.7 million in 2021, then increased by 7.69% to $489.7 million in 2022, then increased by 0.59% to $492.6 million in 2023, then fell by 5.96% to $463.2 million in 2024, then crashed by 32.29% to $313.7 million in 2025.
- Its last three reported values are $313.7 million in Q3 2025, $354.2 million for Q2 2025, and $412.1 million during Q1 2025.